EC approves Pyrukynd for adult alpha- or beta-thalassemia
Bottom line
The European Commission has approved Agios’ Pyrukynd (mitapivat) for adults with anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia, giving the oral pyruvate kinase activator a new EU indication and orphan medicinal product designation. The decision follows a positive CHMP opinion and is based on the Phase 3 ENERGIZE and ENERGIZE-T programs. Agios said the approval makes Pyrukynd the only medicine approved across all EU member states for this broad adult thalassemia population. Outside the U.S., the drug will continue to use the Pyrukynd brand name; in the U.S., the same molecule was approved in December 2025 for adult thalassemia under the brand name Aqvesme. (investor.agios.com)
Why it matters: For veterinary professionals tracking translational medicine, rare disease therapeutics, and the hematology pipeline, this is another example of a metabolism-targeted oral therapy moving into broader real-world use. The EU label covers both transfusion-dependent and non-transfusion-dependent adult patients, which is notable in a category where treatment options can be fragmented by disease subtype and care setting. Phase 3 data in non-transfusion-dependent disease showed hemoglobin benefit and a manageable adverse-event profile, while U.S. regulatory materials also flagged hepatocellular injury concerns that led to a REMS requirement there, underscoring how regional safety management can diverge even for the same product. (sciencedirect.com)
What to watch: Next comes country-level reimbursement and access work across Europe, led with commercial partner Avanzanite Bioscience, which will determine how quickly eligible patients can actually start treatment. (via.tt.se)
Key facts
- Drug
- Pyrukynd (mitapivat)
- Approval
- European Commission approval
- Date
- May 22, 2026
- Indication
- Adults with anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia
- Mechanism
- Oral pyruvate kinase activator
- Evidence base
- Phase 3 ENERGIZE and ENERGIZE-T trials
- Regulatory status
- Orphan medicinal product designation
- Brand note
- Outside the U.S., the drug will continue to use the Pyrukynd brand name
Agios has secured European Commission approval for Pyrukynd (mitapivat) in adults with anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia, expanding the drug beyond its earlier EU use in pyruvate kinase deficiency. The May 22, 2026 decision gives the company a broad adult thalassemia label across the European Union and adds another regulatory milestone for a therapy Agios has been positioning as a disease-modifying oral option in rare hematology. (investor.agios.com)
This approval didn’t come out of nowhere. In October 2025, the EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion on the label expansion, signaling that a final EC decision was likely. Agios had already won U.S. approval for the same active ingredient in adult alpha- or beta-thalassemia on December 23, 2025, though in that market the thalassemia indication carries the Aqvesme brand name rather than Pyrukynd. (investor.agios.com)
The EU decision is based on the Phase 3 ENERGIZE and ENERGIZE-T trials, which studied adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, respectively. Published ENERGIZE results showed improved hemoglobin response versus placebo in non-transfusion-dependent disease, with commonly reported adverse events including headache, initial insomnia, nausea, and upper respiratory tract infection. Agios has separately reported positive ENERGIZE-T results in transfusion-dependent patients, supporting the broader label that now spans both major adult treatment segments. (sciencedirect.com)
Agios and its European commercial partner, Avanzanite Bioscience, are framing the approval as both a scientific and access milestone. In the approval announcement, Italian thalassemia specialist Raffaella Origa said the disease places a substantial burden on quality of life and persistent fatigue, while investigator Antonis Kattamis said an oral therapy has the potential to change care for both transfusion-dependent and non-transfusion-dependent patients. Avanzanite, which signed an exclusive commercialization and distribution agreement with Agios in June 2025 covering the European Economic Area, the UK, and Switzerland, said it will now focus on launch execution and access negotiations with local authorities. (via.tt.se)
There’s also a competitive context here. While other advanced therapies are available for narrower thalassemia populations, including gene-edited Casgevy for certain transfusion-dependent beta-thalassemia patients age 12 and older in the EU, Pyrukynd’s positioning is different: it is an oral small molecule for adults, and its approval spans both alpha- and beta-thalassemia as well as transfusion-dependent and non-transfusion-dependent disease. That breadth is central to Agios’ claim that Pyrukynd is the only medicine approved in all EU member states for this broad adult patient population. (ema.europa.eu)
Why it matters: For veterinary professionals, the direct clinical relevance is limited, but the strategic relevance is real. This is a clean example of how rare disease drug development is increasingly built around pathway-based therapeutics, global Phase 3 programs, and staggered regulatory strategies across jurisdictions. It also shows how safety oversight can vary by market: U.S. approval for thalassemia came with a REMS tied to hepatocellular injury monitoring, while the EU approval proceeds under its own labeling and pharmacovigilance framework. For anyone watching comparative regulation, translational hematology, or orphan drug commercialization, this is a useful case study. (investor.agios.com)
What to watch: The next phase is less about whether the drug works and more about whether patients can get it. Watch for publication of the updated EU product information, country-by-country reimbursement decisions, launch timing through Avanzanite, and any post-approval safety signals or real-world utilization data that shape uptake across Europe. (ema.europa.eu)